Navigation Links
Commencement of GMP Production Project for Lead Anti-Cancer Product PAT-LM1
Date:6/2/2011

MELBOURNE, Australia and PRINCETON, N.J., June 2, 2011 /PRNewswire/ -- Patrys Limited (ASX: PAB) (the "Company"), a biopharmaceutical company focused on the development of novel treatments for cancer, is pleased to announce it has extended its relationship with Laureate Biopharmaceutical Services, Inc. ("Laureate"), to manufacture lead product PAT-LM1 for preclinical and clinical use.  

PAT-LM1 is a natural human antibody that has been shown to have anti-cancer properties, in multiple animal models, including a potent effect in models of pancreatic, lung and colon cancers.  

Laureate is a US based full-service biopharmaceutical contract development and manufacturing organization and has extensive experience in the production of both clinical and marketed products in the biotechnology sector.  

Patrys has an existing arrangement with Laureate for the production of another lead anti-cancer product PAT-SM6.  The PAT-SM6 project at Laureate has been very successful with production yields far exceeding expectations.  PAT-SM6 is currently being evaluated in a human clinical trial targeting patients with melanoma.  

"Laureate has extensive antibody production experience and given the success with PAT-SM6 production, which is very similar to what will be needed for PAT-LM1, Patrys is confident that Laureate can produce yields of PAT-LM1 sufficient to support commercialisation," said Mike Conner, Patrys Vice President, Manufacturing.

Michael A. Griffith, Chief Executive Officer of Laureate Biopharmaceutical Services, Inc added, "We are pleased to be Patrys' chosen manufacturing partner, giving Laureate the opportunity to share in the advancement of their novel anti-cancer products through clinical development."

"From what we have experienced first-hand with the successful production of PAT-SM6, the Patrys' production platform for its natural human antibodies is ro
'/>"/>

SOURCE Laureate Biopharmaceutical Services, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder
2. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
3. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
4. Watson Announces Commencement of Secondary Offering by Selling Stockholder
5. Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer
6. Cogdell Spencer Announces Commencement of Common Stock Offering
7. U.S. Surgeon General Dr. Regina M. Benjamin to Deliver Commencement Address at Albany College of Pharmacy and Health Sciences
8. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
9. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
10. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
11. TPI Receives Production License for Its Anti-diabetic Drug Gliclazide Tablets from Chinas SFDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or ... that it has received final approval for its common shares ... Exchange (the "TSX"). The Company,s common shares will commence trading ... under the trading symbol ,EPI,.  Concurrently, ESSA,s common shares will ... About ESSA Pharma Inc. ESSA Pharma is a ...
(Date:7/28/2015)... 2015 According to a new market ... Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration ... to 2020", published by MarketsandMarkets, the European Injectable Drug Delivery ... $114.7 Billion in 2015, growing at a CAGR of 12.6% ... 230 market data T ables and ...
(Date:7/27/2015)... and PARIS , July ...  and Sanofi have entered into a new global ... treatments in the emerging field of immuno-oncology. As part ... a programmed cell death protein 1 (PD-1) inhibitor currently ... trials in 2016 with new therapeutic candidates based on ...
Breaking Medicine Technology:ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 2ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 2European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 3Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 5Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 6Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 7Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 8
(Date:7/28/2015)... ... ... Every summer, the public is reminded to leave the Fourth of July fireworks ... neighborhoods. Unfortunately, according to a recent report issued by the U.S. Consumer Product Safety ... Injuries Caused by Fireworks Doubled in Last 3 Years ," the number of fireworks-related ...
(Date:7/28/2015)... ... 28, 2015 , ... The PULs Cardiac Test™ identifies asymptomatic ... many of whom are missed by conventional evaluation , A currently unmet ... sub-clinical disease, who are at risk of experiencing a coronary event, and for ...
(Date:7/28/2015)... ... 28, 2015 , ... There has been much discussion in Washington, D.C. ... railroads, often overlooked is the over 740,000 miles of municipal sewer lines ... treatment facilities. According to the American Society of Civil Engineers , the average ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... provider announced HeartPlace will be expanding their cloud presence to support their rapidly ... groups in North Texas, has been serving the Dallas/Fort Worth area for almost ...
(Date:7/28/2015)... ... July 28, 2015 , ... Advanced Fertility Center ... inception in 2010, and Dr Dozortsev , a Reproductive Laboratory Director at ... In 2012, he was succeeded by Dr Gianpiero Palermo, who is credited with the ...
Breaking Medicine News(10 mins):Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 2Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 2Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 3Health News:HeartPlace Announces Cloud Expansion with VAZATA 2Health News:HeartPlace Announces Cloud Expansion with VAZATA 3Health News:Advanced Fertility Center of Texas Is Proud to Announce That Our Lab Director Has Been Re-elected as The American College of Embryology President 2
... 3 /PRNewswire-FirstCall/ - Two of DiagnoCure Inc.,(TSX: CUR) products, ... GCC for the staging of colorectal cancer, were discussed ... to molecular diagnostics., Yesterday, on June 2nd, DiagnoCure ... Assay Society Meeting, held in Coral,Springs, Florida, with a ...
... safe in both HIV-infected and HIVuninfected men , ... HIV disease, according to research published in PLoS Medicine. ... circumcision in the rural Rakai district of Uganda, Ron ... Hopkins University and colleagues found approximately a 3% rate ...
... Grant Will Fund Chicago Latino Outreach Program and National Latino ... ... The American Diabetes,Association (ADA) was recently awarded a $450,000 grant from ... National Latino,Outreach Toolkit. Diabetes is an urgent health problem in the ...
... Inc.,(NYSE: MED ) announced today that Michael S. ... a presentation at the,Canaccord Adams Diabetes & Obesity Conference ... the Hotel Nikko San Francisco., Interested parties can ... http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2301640 . The web,cast will be available for 60 ...
... precursors of autoantibody-secreting cells, have emerged as promising ... arthritis (RA). In particular, B cell depletion ... for RA patients resistant to standard disease-modifying antirheumatic ... blockers. In large trials, about half of ...
... 2 Katzen Eye Group is happy to,announce ... CRT.,Paragon CRT temporarily corrects nearsightedness (myopia) with or ... health of their patients, Katzen Eye Group is,continually ... vision care. Paragon CRT is a specially designed ...
Cached Medicine News:Health News:DiagnoCure's molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings 2Health News:DiagnoCure's molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings 3Health News:Study finds circumcision safe in both HIV-infected and HIV-uninfected men 2Health News:Study finds circumcision safe in both HIV-infected and HIV-uninfected men 3Health News:American Diabetes Association Receives $450,000 Grant From Abbott Fund for Latino Community Initiatives 2Health News:Medifast, Inc. to Present at the Canaccord Adams Diabetes & Obesity Conference 2Health News:Study of anti-CD20 therapy effective B cell depletion 2Health News:Katzen Eye Group Announces a New Option in Vision Correction Technology for Patients 2
EnTrust family of ICDs provides a suite of features for total AT/AF co-morbidity management, including diagnostics to detect when your patient develops AT/AF, and both termination and intervention th...
... a key participant in the area of ... decade. Previous Medtronic autotransfusion systems allowed clinicians ... well as to determine requirements for a ... (PRP) for a small amount of autologous ...
... SJM Pericardial Patch with EnCap technology ... vessel reconstruction/repair and for pericardial closure. ... offers surgeons durability and flexibility, plus ... patches. Equally important in a tissue ...
... triaxial catheter design and ergonomic handle ... proprietary radiopaque Nitinol markers on the ... stent enhance visibility. Corrugated ring design ... the nested ring pattern minimizes stent ...
Medicine Products: